Xtl Biopharmaceuticals

(NASDAQ) XTLB

Current Price$2.54

Market Cap$6.39M

Since IPO (2005)-100%

5 Year-83%

1 Year-44%

1 Month+18%

Xtl Biopharmaceuticals Financials at a Glance

Market Cap

$6.39M

Revenue (TTM)

$451.00K

Net Income (TTM)

-$1.03M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$2.54

Volume

340

Open

$2.44

Price

$2.54

Volume

340

Open

$2.44

Previous Close

$2.70

Daily Range

$2.36 - $2.74

52-Week Range

$2.01 - $10.28

Estimated Earnings Date

Apr 29, 2026

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$2.54

Volume

340

Open

$2.44

Previous Close

$2.70

Daily Range

$2.36 - $2.74

52-Week Range

$2.01 - $10.28

Estimated Earnings Date

Apr 29, 2026

XTLB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xtl Biopharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Shlomo Spokone Shalev, MBA

Website

www.xtlbio.com

Headquarters

Ramat Gan, 5218102, IL

XTLB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-269.02%

Return on Capital

-11253.33%

Return on Assets

-4198.19%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.39M

Shares Outstanding

2.37M

Volume

340

Avg. Volume

1.98M

Financials (TTM)

Gross Profit

$119.00K

Operating Income

-$2.17M

EBITDA

-$791.25K

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$144.00K

Total Debt

$269.00K

Xtl Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2024YOY CHG

Revenue

$289.00K

N/A

Gross Profit

-$43.00K

N/A

Gross Margin

-14.88%

N/A

Market Cap

$6.39M

N/A

Market Cap/Employee

$638.71K

N/A

Employees

N/A

Net Income

-$255.00K

+10.2%

EBITDA

-$429.25K

-51.1%

Quarterly Fundamentals

Name

Q4 2024YOY CHG

Total Cash

$144.00K

-93.8%

Total Debt

$269.00K

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$269.00K

N/A

Return on Assets

-41.98%

N/A

Return on Invested Capital

6.65%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RADXRadiopharm Theranostics Limited

RADXRadiopharm Theranostics Limited$4.37+2.82%

TCRTAlaunos Therapeutics, Inc.

TCRTAlaunos Therapeutics, Inc.$2.08-3.70%

KTTAPasithea Therapeutics Corp.

KTTAPasithea Therapeutics Corp.$0.55-3.02%

QNRXQuoin Pharmaceuticals, Ltd.

QNRXQuoin Pharmaceuticals, Ltd.$4.58-2.76%

ENSCEnsysce Biosciences, Inc.

ENSCEnsysce Biosciences, Inc.$0.28-5.87%

VYNEVYNE Therapeutics Inc.

VYNEVYNE Therapeutics Inc.$0.68-0.16%

CYCNCyclerion Therapeutics, Inc.

CYCNCyclerion Therapeutics, Inc.$3.43-1.72%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NFLXNetflix

NFLXNetflix$77.73+0.05%

NUNu Holdings

NUNu Holdings$13.60+0.02%

PATHUiPath

PATHUiPath$11.68+0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$39.95+0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.35-0.05%

CLROClearOne

CLROClearOne$6.48+1.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.30-0.15%

Questions About XTLB

What is the current price of Xtl Biopharmaceuticals?

Xtl Biopharmaceuticals is trading at $2.70 per share.

What is the 52-week range for Xtl Biopharmaceuticals?

Over the past 52 weeks, Xtl Biopharmaceuticals has traded between $2.01 and $10.28.

How much debt does Xtl Biopharmaceuticals have?

As of the most recent reporting period, Xtl Biopharmaceuticals reported total debt of $138.00K.

How much cash does Xtl Biopharmaceuticals have on hand?

Xtl Biopharmaceuticals reported $371.00K in cash and cash equivalents in its most recent financial results.

What is Xtl Biopharmaceuticals’s dividend yield?

Xtl Biopharmaceuticals does not currently have a dividend yield.

Xtl Biopharmaceuticals

Xtl Biopharmaceuticals Financials at a Glance

XTLB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Xtl Biopharmaceuticals

XTLB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Xtl Biopharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About XTLB

What is the current price of Xtl Biopharmaceuticals?

What is the 52-week range for Xtl Biopharmaceuticals?

How much debt does Xtl Biopharmaceuticals have?

How much cash does Xtl Biopharmaceuticals have on hand?

What is Xtl Biopharmaceuticals’s dividend yield?

Premium Investing Services